Please login to the form below

Not currently logged in

The Liver Meeting 2019

This page shows the latest The Liver Meeting 2019 news and features for those working in and with pharma, biotech and healthcare.

Novartis makes case for NASH candidate tropifexor

Novartis makes case for NASH candidate tropifexor

This condition is a type of non-alcoholic fatty liver disease (NAFLD), which causes an accumulation of fat in the liver which leads to chronic inflammation and fibrosis. ... The full, detailed data is due to be presented at The Liver Meeting 2019 taking

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs


Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

Ask the writers: Transitioning from academia to medical writing
Porterhouse Medical's talented writers talk about their transition from academia and give advice to those people considering a career in medical writing...
Strategic launch planning: familiar framework, new mindset
By James Aird...
How to embrace behavioural science principles in healthcare MR...